UKIPO rejects Novartis’s TM opposition attempt

Switzerland-based Novartis has failed to convince the UK Intellectual Property Office (IPO) that a trademark applied-for by Boston Healthcare should not be registered.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Novartis and others in ‘unprecedented’ COVID-19 partnership

27 March 2020 A consortium of life sciences companies including Novartis, Bristol Myers Squibb and GSK have united to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19.

Big Pharma

Novartis sues Chinese firm over attempts to make generic heart failure drug

30 September 2021 Pharma giant Novartis has filed a patent suit against Crystal Pharmaceuticals after the rival sought to create a generic version of its heart failure drug Entresto.

article

UKIPO appoints permanent chief executive

13 December 2022 Interim CEO becomes permanent | Appointee “brings broad leadership experience and deep knowledge of the IPO” | Appointment “concludes a period of change at IPO”.

More on this story

Americas

Novartis and others in ‘unprecedented’ COVID-19 partnership

Big Pharma

Novartis sues Chinese firm over attempts to make generic heart failure drug

30 September 2021 Pharma giant Novartis has filed a patent suit against Crystal Pharmaceuticals after the rival sought to create a generic version of its heart failure drug Entresto.

article

UKIPO appoints permanent chief executive

13 December 2022 Interim CEO becomes permanent | Appointee “brings broad leadership experience and deep knowledge of the IPO” | Appointment “concludes a period of change at IPO”.

More on this story

Americas

Novartis and others in ‘unprecedented’ COVID-19 partnership

Big Pharma

Novartis sues Chinese firm over attempts to make generic heart failure drug

30 September 2021 Pharma giant Novartis has filed a patent suit against Crystal Pharmaceuticals after the rival sought to create a generic version of its heart failure drug Entresto.

article

UKIPO appoints permanent chief executive

13 December 2022 Interim CEO becomes permanent | Appointee “brings broad leadership experience and deep knowledge of the IPO” | Appointment “concludes a period of change at IPO”.

More features

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird

Sandoz wins $137.2m payout for lost profits in generic launch

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts

WBD to merge with firm to create ‘powerhouse’ practice

‘Be prepared, and don’t assume at the UPC’: Christopher Stothers

UKIPO rejects Novartis’s TM opposition attempt

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features